Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...

Immunotherapy has transformed cancer treatment, but persistent challenges, such as T cell exhaustion, limited persistence, and variability in response, continue to impact therapeutic success.

A new Research Triangle company, Persistence Therapeutics, is developing a small, implantable device that generates and delivers genetically engineered T cells directly inside the body. These cells, ...

Immune checkpoint blockade therapy relies on releasing a natural brake in the immune system to fight cancer. This therapy activates the body’s CD8+ cytotoxic T cells, which mount an attack against ...

Researchers found that activating the STING pathway with an experimental agonist reduced meningioma growth, triggered ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue ...

Mayo Clinic researchers and collaborators have identified a previously unrecognized way lung tumors weaken the immune system, ...

Immunotherapy—which activates the body's own immune system to kill cancer cells—has not worked well against a rare and fatal liver cancer, but a new study finds an existing FDA-approved drug may allow ...

Immune checkpoint inhibitors, popularized by Allison and Honjo’s Nobel Prize, were one of the first cancer immunotherapies that gained FDA approval. In the 1990s, Allison and Honjo identified the ...

Scientists have designed an immunotherapy that reduces plaque in the arteries of mice, presenting a possible new treatment ...